Spots Global Cancer Trial Database for advanced lung cancer
Every month we try and update this database with for advanced lung cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Support for Cancer Patients Awaiting News | NCT06199570 | Lung Cancer | Adapted Stress ... Enhanced Usual ... | 18 Years - | Hackensack Meridian Health | |
| Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) | NCT00373204 | Lung Cancer | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | NCT04670445 | Stage IV Melano... Advanced Lung C... Stage IV Non-Sm... Unresectable No... Unresectable St... Small Cell Lung... Stage IV Merkel... Stage IV Cutane... Stage IV Basal ... Stage IV Breast... Stage IV Colore... Stage IV Gastri... Stage IV Esopha... Stage IV Hepato... Stage IV Renal ... Stage IV Bladde... Stage IV Head a... Stage IV Cervic... Stage IV Endome... Stage IV Mesoth... Immunotherapy Immune Checkpoi... | Educational Vid... Usual Care | 18 Years - | Massachusetts General Hospital | |
| Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) | NCT00373204 | Lung Cancer | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | NCT00365183 | Non-Small Cell ... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | NCT00365183 | Non-Small Cell ... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer | NCT03751592 | Advanced Lung C... | Chlorogenic aci... | 18 Years - | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | |
| A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC | NCT04672369 | Advanced Lung C... | IBI939 Sintilimab | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | NCT03004105 | Malignant Neopl... Advanced Lung C... Recurrent Nonsm... | Selumetinib Durvalumab Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | NCT05664971 | Advanced Lung C... | Recombinant hum... Toripalimab Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Etoposide | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Cambridge Brain Mets Trial 1 | NCT02768337 | Lung Cancer Breast Cancer Brain Cancer Advanced Breast... Advanced Lung C... | Afatinib 2 Gy targeted r... 4 Gy targeted r... | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC | NCT05198154 | Advanced Lung N... | ctDNA detection | 18 Years - 75 Years | Second Xiangya Hospital of Central South University | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment. | NCT06326086 | Advanced Lung C... Sarcopenia | Chemotherapy dr... Targeted Agent Immunotherapy | 18 Years - | Prince of Songkla University | |
| Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | NCT00858364 | Non-Small Cell ... Anemia Cancer Lung Cancer | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment. | NCT06326086 | Advanced Lung C... Sarcopenia | Chemotherapy dr... Targeted Agent Immunotherapy | 18 Years - | Prince of Songkla University | |
| Descriptors and Predictors of Burden and Information Needs | NCT04069494 | Advanced Lung C... Symptoms | questionnaires | 18 Years - | Chulabhorn Cancer Center | |
| A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) | NCT00102505 | Non-Small-Cell ... Carcinoma, Bron... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients | NCT02414672 | Lung Cancer | CareSTEPS | 18 Years - | Baylor College of Medicine | |
| Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer | NCT06244355 | Lung Cancer | Extra blood tub... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer | NCT05431569 | Advanced Lung C... | 6MW3211 | 18 Years - | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia | NCT00481624 | Anemia | Epoetin Alfa pl... | 18 Years - | University of Louisville | |
| Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer | NCT02801734 | Advanced Lung C... | EQUIP | 18 Years - 99 Years | National Cancer Centre, Singapore | |
| Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | NCT00137839 | Adenocarcinoma Non-small Cell ... | Erlotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease) | NCT06054854 | Lung Nodule Lung Cancer | Extra blood sam... | 18 Years - | University Hospital, Toulouse | |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer | NCT00737867 | Advanced Non-Sm... | Vinorelbine Gemcitabine Vinorelbine Carboplatin | 18 Years - | The Norwegian Lung Cancer Study Group | |
| A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer | NCT06183762 | Advanced Lung C... | No treatment is... | 18 Years - | Hunan Province Tumor Hospital | |
| Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer | NCT02132325 | Pancreatic Canc... Non-Small-Cell ... | Dignity Therapy | 19 Years - | Mayo Clinic | |
| Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | NCT01700400 | Non Small Cell ... | Everolimus Pemetrexed Carboplatin Bevacizumab | 18 Years - | Cancer Research and Biostatistics Clinical Trials Consortium | |
| Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer | NCT05815862 | Advanced Lung C... Ovarian Cancer | AL2846 capsule | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator | NCT04352335 | Advanced Lung C... | 20 Years - | Chung Shan Medical University | ||
| CAR-T Cell Immunotherapy for Advanced Lung Cancer | NCT03330834 | Advanced Lung C... | CAR-T cells to ... | 18 Years - 65 Years | Sun Yat-sen University | |
| Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator | NCT04352335 | Advanced Lung C... | 20 Years - | Chung Shan Medical University | ||
| Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | NCT00137839 | Adenocarcinoma Non-small Cell ... | Erlotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer | NCT03501056 | Advanced Lung C... | Activated CIK a... Cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| Study of Participants With Advanced Non-Small Cell Lung Cancer | NCT00948675 | Advanced Non-Sm... | Pemetrexed Carboplatin Paclitaxel Bevacizumab | 18 Years - | Eli Lilly and Company | |
| Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | NCT04128800 | Small Cell Lung... | Apatinib S-1 | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer | NCT04672356 | Advanced Lung C... | IBI939 Sintilimab | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer | NCT00422500 | Lung Cancer | Questionnaire Telephone Inter... Blood Samples | 18 Years - | M.D. Anderson Cancer Center | |
| Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer | NCT02801734 | Advanced Lung C... | EQUIP | 18 Years - 99 Years | National Cancer Centre, Singapore | |
| Feasibility and Preliminary Efficacy of Exercise During Immunotherapy in Patients With Lung Cancer: The INHALE Trial | NCT06026111 | Advanced Lung C... | High-Intensity ... Moderate-Intens... | 18 Years - | Dana-Farber Cancer Institute | |
| JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | NCT05664971 | Advanced Lung C... | Recombinant hum... Toripalimab Docetaxel Pemetrexed Cisplatin Carboplatin Paclitaxel Etoposide | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients | NCT00457119 | Non Small Cell ... | RAD001 | 23 Years - 76 Years | Novartis | |
| Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | NCT00466466 | Small-Cell Lung... | Everolimus | 18 Years - | Novartis | |
| Immunotherapy With Racotumomab in Advanced Lung Cancer | NCT01460472 | NSCLC Lung Cancer, No... | Racotumomab Best Support Tr... | 18 Years - | Recombio SL | |
| Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients | NCT01240447 | Advanced Non-sm... | racotumomab Best support tr... | 21 Years - | Laboratorio Elea Phoenix S.A. | |
| A Study of LY3023414 in Participants With Advanced Cancer | NCT01655225 | Advanced Cancer Metastatic Canc... Non-Hodgkin's L... Metastatic Brea... Malignant Mesot... Non-small Cell ... | LY3023414 Midazolam Fulvestrant Pemetrexed Cisplatin Abemaciclib Letrozole | 18 Years - | Eli Lilly and Company | |
| A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer | NCT06183762 | Advanced Lung C... | No treatment is... | 18 Years - | Hunan Province Tumor Hospital | |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer | NCT00737867 | Advanced Non-Sm... | Vinorelbine Gemcitabine Vinorelbine Carboplatin | 18 Years - | The Norwegian Lung Cancer Study Group | |
| IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | NCT05805956 | Advanced Solid ... Advanced Lung C... Advanced Gastri... Advanced Cholan... | IMM2902 | 18 Years - 75 Years | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | |
| Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer | NCT00737867 | Advanced Non-Sm... | Vinorelbine Gemcitabine Vinorelbine Carboplatin | 18 Years - | The Norwegian Lung Cancer Study Group | |
| Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL) | NCT04575831 | Advanced Lung C... | Exercise, Nutri... | - | University of Calgary | |
| Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease) | NCT06054854 | Lung Nodule Lung Cancer | Extra blood sam... | 18 Years - | University Hospital, Toulouse | |
| Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients | NCT00457119 | Non Small Cell ... | RAD001 | 23 Years - 76 Years | Novartis | |
| Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC | NCT04629027 | Non Small Cell ... | Immune checkpoi... | 18 Years - | Peking University Cancer Hospital & Institute | |
| Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer | NCT00735878 | Non Small Cell ... Lung Cancer | ABT-751 and Car... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Feasibility and Preliminary Efficacy of Exercise During Immunotherapy in Patients With Lung Cancer: The INHALE Trial | NCT06026111 | Advanced Lung C... | High-Intensity ... Moderate-Intens... | 18 Years - | Dana-Farber Cancer Institute | |
| Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer | NCT06228209 | Advanced Heart ... Advanced Non-co... Advanced Lung C... | Tier - Palliati... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| CAR-T Cell Immunotherapy for Advanced Lung Cancer | NCT03330834 | Advanced Lung C... | CAR-T cells to ... | 18 Years - 65 Years | Sun Yat-sen University | |
| Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer | NCT02132325 | Pancreatic Canc... Non-Small-Cell ... | Dignity Therapy | 19 Years - | Mayo Clinic | |
| Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer | NCT03751592 | Advanced Lung C... | Chlorogenic aci... | 18 Years - | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | |
| Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | NCT02638090 | Lung Cancer Non-small Cell ... | Vorinostat Pembrolizumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer | NCT06244355 | Lung Cancer | Extra blood tub... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | NCT00858364 | Non-Small Cell ... Anemia Cancer Lung Cancer | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers | NCT01579994 | Advanced Lung C... | Ganetespib (STA... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer | NCT05852002 | Advanced Lung C... | 35 kDa hyaluron... | 18 Years - 80 Years | Nakhia Impex LLC | |
| Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) | NCT00373204 | Lung Cancer | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients | NCT02414672 | Lung Cancer | CareSTEPS | 18 Years - | Baylor College of Medicine | |
| A Study of LY3023414 in Participants With Advanced Cancer | NCT01655225 | Advanced Cancer Metastatic Canc... Non-Hodgkin's L... Metastatic Brea... Malignant Mesot... Non-small Cell ... | LY3023414 Midazolam Fulvestrant Pemetrexed Cisplatin Abemaciclib Letrozole | 18 Years - | Eli Lilly and Company | |
| TIL Therapy for Patients With Advanced Solid Tumors | NCT06107894 | Advanced Breast... Advanced Lung C... | Tumor-infiltrat... IL-2 | 20 Years - | NeogenTC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
